Testing AI breath ammonia kidney results for pharmacist medication advice in diabetes
Reviews past hospital cases of adults with type 2 diabetes and kidney disease.
Plain-language title generated from the registry record
Registry title: Impact of AI-Based Breath Ammonia Kidney Function Results on Clinical Pharmacist Medication Recommendations
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Shanghai Pudong HospitalShanghai, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Pudong Hospital
- Trial code
- NCT07888855
- Record updated
- 22 October 2026
- Original description
This retrospective study evaluates whether providing clinicians with artificial intelligence (AI)-based kidney function results from a breath ammonia test can improve the quality of medication recommendations made by clinical pharmacists. Using historical inpatient cases from Shanghai Pudong Hospital, each case was evaluated under two information conditions: one with standard clinical information only, and one with the additional AI-based breath test kidney function results. Independent experts blindly scored the medication recommendations. The study aims to determine whether the breath test AI information adds meaningful clinical value to pharmacist decision-making.Read full original descriptionShow less
A Real World Study of Remote Continuous Noninvasive Monitoring and Diagnosis of Diabetic Kidney Disease Using a Two Dimensional Heterostructure Based Wearable NH₃ Sensor
This retrospective study evaluates whether providing clinicians with artificial intelligence (AI)-based kidney function results from a breath ammonia test can improve the quality of medication recommendations made by clinical pharmacists. Using historical inpatient cases from Shanghai Pudong Hospital, each case was evaluated under two information conditions: one with standard clinical information only, and one with the additional AI-based breath test kidney function results. Independent experts blindly scored the medication recommendations. The study aims to determine whether the breath test AI information adds meaningful clinical value to pharmacist decision-making.
Inclusion: Historical cases with completed breath test and AI kidney function classification results; Complete standardized case records from the breath test hospitalization; Serum creatinine and eGFR results available within 7 days before or after the breath test, serving as an independent reference standard; Case data sufficient to support the pharmacist in making medication recommendations.
Exclusion: Missing standardized case data preventing independent medication evaluation; Cases that cannot maintain information isolation between Condition A and Condition B; Breath test and reference blood test interval exceeding 7 days; Case in acute kidney injury (AKI) state.